STOCK TITAN
  1. Home
  2. News
  3. SLS

SELLAS Life Sciences Group Inc - SLS STOCK NEWS

Welcome to our dedicated news page for SELLAS Life Sciences Group (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on SELLAS Life Sciences Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SELLAS Life Sciences Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SELLAS Life Sciences Group's position in the market.

News
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announces the presentation of data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 at the 2024 ESH Conference. The presentation will be given by Dr. Tapan Kadia, detailing the Phase 1 Dose-Escalation Study of GFH009 in Acute Myeloid Leukemia. The session will take place on Sunday, March 3, 2024, at 12 pm CET in Stockholm, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences clinical trial
-
News
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia
Rhea-AI Summary
GenFleet Therapeutics (GFH), a clinical-stage biotechnology company, received fast track and orphan drug designations from the FDA for its highly selective CDK9 inhibitor, GFH009, for the treatment of relapsed/refractory peripheral T-cell lymphomas (PTCL) and acute myeloid leukemia (AML). The company is conducting phase II studies for both indications, with positive clinical responses observed in previous studies. GenFleet's partner, Sellas Life Sciences, is also undertaking a phase II trial for GFH009 in combination with other drugs for treating r/r AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
clinical trial
-
News
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
Rhea-AI Summary
SELLAS Life Sciences Group, ticker symbol SLS, announced the completion of Phase 2a enrollment for SLS009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia (AML). The Fast Track Designation from the FDA underscores the potential of SLS009, with positive topline Phase 2a data showing significant anti-leukemic effects and an 89% survival rate in the 45 mg dose cohort. The company aims to deliver a potentially groundbreaking treatment to AML patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
clinical trial
News
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced the pricing of a public offering for the purchase and sale of 12,000,000 shares of common stock and accompanying warrants, resulting in total gross proceeds of $9.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.26%
Tags
offering
-
News
SELLAS Life Sciences Announces Proposed Public Offering
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced a public offering of shares of its common stock and warrants to purchase shares of common stock. The net proceeds will be used for funding ongoing operations, clinical development of existing product candidates, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.26%
Tags
offering
-
News
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) will host a corporate update webinar to discuss the positive clinical progress and upcoming milestones for their cancer therapy programs, Galinpepimut-S (GPS) and SLS009.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
News
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced positive follow-up clinical/immune-response data from a Phase 1 trial of galinpepimut-S (GPS) combined with nivolumab in patients with relapsed malignant pleural mesothelioma. The study showed a 70.3 weeks median overall survival, a 208.3% increase in survival time for patients with GPS-specific immune response, and a 30% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
clinical trial
-
News
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced that the U.S. FDA has granted Orphan Drug Designation for SLS009, a novel CDK9 inhibitor, for the treatment of r/r Peripheral T-cell Lymphomas. The drug showed a 36.4% clinical response rate, higher than the standard of care's 25.8%. The Phase 1b/2 study in PTCL is ongoing, with top-line data expected in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.74%
Tags
clinical trial
-
News
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has completed enrollment in the 45 mg safety cohort for its ongoing Phase 2a clinical trial of SLS009, a CDK9 inhibitor, in combination with venetoclax and azacitidine for patients with relapsed/refractory acute myeloid leukemia (AML). The Safety Monitoring Committee has recommended proceeding to the Phase 2 dose level of 60 mg, with early data expected around year-end 2023. The company reported significant anti-leukemic effects and no dose limiting toxicities in the 45 mg cohort, indicating important progress in the clinical advancement of SLS009.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.15%
Tags
clinical trial
News
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) will host a corporate update webinar on January 3, 2024, at 8:30 a.m. Eastern Time. Angelos Stergiou, MD, ScD h.c., President and CEO, will discuss the Company’s achievements in 2023 and provide an outlook for 2024. Key opinion leaders will discuss the Phase 3 registrational REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia and the clinical program for SLS009, the Company’s CDK9 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences
Stock SLS logo
SELLAS Life Sciences Group Inc

Nasdaq:SLS

SLS Rankings

#4376 Ranked by Market Cap
#5312 Ranked by Stock Gains
N/A Ranked by Dividends

SLS Stock Data

75.40M
55.63M
0.5%
10.45%
9.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Camden

About SLS

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.